HER2 过表达和扩增存在于一部分卵巢黏液性癌中，并且可以用曲妥珠单抗治疗进行靶向治疗。
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.
机构信息
Department of Gynaecology and Obstetrics, University of British Columbia, Vancouver, BC, Canada.
出版信息
BMC Cancer. 2009 Dec 10;9:433. doi: 10.1186/1471-2407-9-433.
BACKGROUND
The response rate of ovarian mucinous carcinomas to paclitaxel/carboplatin is low, prompting interest in targeted molecular therapies. We investigated HER2 expression and amplification, and the potential for trastuzumab therapy in this histologic subtype of ovarian cancer.
METHODS
HER2 status was tested in 33 mucinous carcinomas and 16 mucinous borderline ovarian tumors (BOT)). Five cases with documented recurrence and with tissue from the recurrence available for testing were analyzed to determine whether HER2 amplification status changed over time. Three prospectively identified recurrent mucinous ovarian carcinomas were assessed for HER2 amplification and patients received trastuzumab therapy with conventional chemotherapy.
RESULTS
Amplification of HER2 was observed in 6/33 (18.2%) mucinous carcinomas and 3/16 (18.8%) BOT. HER2 amplification in primary mucinous carcinomas was not associated with an increased likelihood of recurrence. The prospectively identified recurrent mucinous carcinomas showed overexpression and amplification of HER2; one patient's tumor responded dramatically to trastuzumab in combination with conventional chemotherapy, while another patient experienced an isolated central nervous system recurrence after trastuzumab therapy.
CONCLUSION
HER2 amplification is relatively common in ovarian mucinous carcinomas (6/33, 18.2%), although not of prognostic significance. Trastuzumab therapy is a treatment option for patients with mucinous carcinoma when the tumor has HER2 amplification and overexpression.
背景
卵巢黏液性癌对紫杉醇/卡铂的反应率较低，这促使人们对靶向分子治疗产生了兴趣。我们研究了 HER2 的表达和扩增情况，以及曲妥珠单抗治疗这种卵巢癌组织学亚型的潜力。
方法
在 33 例黏液性癌和 16 例黏液性交界性卵巢肿瘤（BOT）中检测了 HER2 状态。对 5 例有记录复发且有可用于检测的复发病灶组织的病例进行了分析，以确定 HER2 扩增状态是否随时间而改变。对 3 例经前瞻性识别的复发性黏液性卵巢癌进行了 HER2 扩增评估，患者接受曲妥珠单抗联合常规化疗治疗。
结果
在 33 例黏液性癌中有 6/33（18.2%）和在 16 例 BOT 中有 3/16（18.8%）观察到 HER2 扩增。原发性黏液性癌中 HER2 扩增与复发的可能性增加无关。前瞻性识别的复发性黏液性癌表现出 HER2 的过表达和扩增；1 例患者的肿瘤对曲妥珠单抗联合常规化疗反应显著，而另 1 例患者在曲妥珠单抗治疗后出现孤立性中枢神经系统复发。
结论
卵巢黏液性癌中 HER2 扩增相对常见（6/33，18.2%），但无预后意义。当肿瘤存在 HER2 扩增和过表达时，曲妥珠单抗治疗是黏液性癌患者的一种治疗选择。
Zotero 插件